Fate Therapeutics (FATE) Net Margin (2016 - 2025)
Fate Therapeutics' Net Margin history spans 14 years, with the latest figure at 2374.07% for Q4 2025.
- For Q4 2025, Net Margin rose 73744.0% year-over-year to 2374.07%; the TTM value through Dec 2025 reached 2056.15%, down 64035.0%, while the annual FY2025 figure was 2056.15%, 64035.0% down from the prior year.
- Net Margin reached 2374.07% in Q4 2025 per FATE's latest filing, down from 1847.21% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 42.21% in Q1 2023 to a low of 6236.23% in Q2 2023.
- Average Net Margin over 5 years is 1520.61%, with a median of 1076.97% recorded in 2024.
- Peak YoY movement for Net Margin: crashed -579226bps in 2023, then surged 564178bps in 2024.
- A 5-year view of Net Margin shows it stood at 404.74% in 2021, then surged by 66bps to 138.74% in 2022, then plummeted by -1778bps to 2605.07% in 2023, then decreased by -19bps to 3111.51% in 2024, then increased by 24bps to 2374.07% in 2025.
- Per Business Quant, the three most recent readings for FATE's Net Margin are 2374.07% (Q4 2025), 1847.21% (Q3 2025), and 1785.37% (Q2 2025).